Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified June 2014 by University of Washington
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT02157051
First received: June 3, 2014
Last updated: June 4, 2014
Last verified: June 2014

June 3, 2014
June 4, 2014
November 2014
October 2016   (final data collection date for primary outcome measure)
  • Incidence of toxicity per Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    The type and grade of toxicities noted during the immunization regimen will be summarized. Adverse events noted by the investigator/designated clinical research staff will be tabulated according to the affected body system. Descriptive statistics will be used to summarize changes from baseline in clinical and/or laboratory parameters.
  • Immunologic efficacy defined as achievement of a statistically significant increase in Th1 cell immunity for at least 50% of the immunizing antigens as compared to baseline [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT02157051 on ClinicalTrials.gov Archive Site
  • Memory Th1 dominant immune response to all five antigens over time [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Modulation of T-regulatory (Treg) cells with vaccination [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
    Treg defined as present or absent, and the probability will be estimated as a simple proportion.
  • Modulation of MDSC with vaccination [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
    MDSC defined as present or absent, and the probability will be estimated as a simple proportion.
Same as current
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients

This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast cancer. Multiantigen DNA plasmid-based vaccine may target immunogenic proteins expressed in breast cancer stem cells which are the component of breast cancer that is resistant to chemotherapy and has the ability to spread. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells.

PRIMARY OBJECTIVES:

I. To determine the safety of intradermal administration of up to 3 escalating doses of CD105/Yb-1/SOX2 CDH3/MDM2 multiplasmid vaccine (STEMVAC) in patients with HER2-negative advanced stage breast cancer.

II. To determine the most immunogenic dose of STEMVAC in patients with HER2-negative advanced stage breast cancer.

SECONDARY OBJECTIVES:

I. To determine whether a STEMVAC T helper 1 cells (Th1) polyepitope plasmid based vaccine elicits a persistent memory T cell response and whether immunity can be further enhanced/maintained by two additional STEMVAC vaccines (boosters) given 3 and 9 months after the priming regimen.

II. To evaluate whether STEMVAC vaccination modulates T regulatory cells and myeloid-derived suppressor cells (MDSC).

OUTLINE: This is a dose-escalation study.

Patients receive CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine with rhuGM-CSF intradermally (ID) every 28 days for 3 months and booster vaccines at 6 and 12 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up twice yearly for 5 years.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HER2-negative Breast Cancer
  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Biological: CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine
    Given ID
    Other Name: STEMVAC Th1 polyepitope plasmid-based vaccine
  • Other: laboratory biomarker analysis
    Correlative studies
Experimental: Treatment (STEMVAC)
Patients receive CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine with rhuGM-CSF ID every 28 days for 3 months and booster vaccines at 6 and 12 months in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Biological: CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine
  • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
Not Provided
October 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have:

    • No evidence of disease (NED), or
    • Stable bone only disease
  • Patients who have completed standard of care and recovered with mild to no residual toxicity from recent therapy
  • Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy, prior to enrollment
  • Patients must be at least 28 days post systemic steroids prior to enrollment
  • Patients on bisphosphonates and/or endocrine therapy are eligible
  • Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =< 1
  • Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
  • Estimated life expectancy of more than 6 months
  • White blood cells (WBC) >= 3000/mm^3
  • Hemoglobin (Hgb) >= 10 mg/dl
  • Serum creatinine =< 1.2 mg/dl when adjusted for body surface area (BSA) or creatinine clearance > 60 ml/min
  • Total bilirubin =< 1.5 mg/dl
  • Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 2 times upper limit of normal (ULN)
  • Blood glucose < 1.5 ULN
  • Postmenopausal women determined by one of the following:

    • Bilateral surgical oophorectomy
    • Age greater than or equal 60 years
    • Age < 60 years, with amenorrhea greater than or equal to 12 months and follicle-stimulating hormone within postmenopausal range
  • Non-menopausal female patients must agree to contraception for the remainder of their childbearing years
  • Male patients must use an acceptable form of contraception throughout the course of the study

Exclusion Criteria:

  • Patients with any of the following cardiac conditions:

    • Symptomatic restrictive cardiomyopathy
    • Unstable angina within 4 months prior to enrollment
    • New York Heart Association functional class III-IV heart failure on active treatment
    • Symptomatic pericardial effusion
  • Patients at risk for gastrointestinal bleeding (example: peptic ulcer disease, prolonged daily non-steroidal anti-inflammatory use)
  • Patients with any contraindication to receiving recombinant human granulocyte-macrophage colony stimulating factor; GM-CSF; LEUKINE® (sargramostim) (rhuGM-CSF) based products
  • Patients with any clinically significant autoimmune disease uncontrolled with treatment
  • Patients who are simultaneously enrolled in any other treatment study
  • Patients who are pregnant or breastfeeding
Both
18 Years and older
No
United States
 
NCT02157051
9140, NCI-2014-01070, 137, 9140, P30CA015704
No
University of Washington
University of Washington
National Cancer Institute (NCI)
Principal Investigator: Mary Disis Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
University of Washington
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP